PARA AMINO BENZOIC ACID BASED NANOTUBES

摘要

The invention comprises nanotubes and a process for making same and its intermediates comprising a drug moiety or its derivative/s as a structural moiety that further has side chain/s capable of promoting self aggregation and/or performing a functionality. The side chain/s may be the side chains may be mono or a multiple of alkyl chain/s having even number or odd number of carbon atoms that may be substituted or unsubstituted capable of creating simple or complex self aggregating assemblies. Particular illustration comprises a p-amino benzoic acid (PABA) drug moiety or its derivative as a structural moiety comprising 4-alkylamido-N-pyridin-2yl-benzamide with a lauric (C=12) or stearic (C=18) side chain as particular illustration. 4-alkylamido-N-pyridin-2yl-benzamide and 4-Amino-N- pyridine-2 yl-benzamide, N-(Pyridine-2-yl)-4-dodecanamido-benzamide and N-(Pyridin-2- yl)-4-stearamidobenzamide are intermediates for this invention and are novel compounds. Nanotubes having stearic side chain are disclosed to have intrinsic fluorescence and are useful for in vivo Conjugation of an active ingredient, illustrated by Rhodamine B with the said nanotube has been disclosed, or nanorod, wherein the active ingredient has a function to perform when absorbed or introduced in the body of a cell or an organism or for delivery of genetic material inside a cell or to an organism. The function may include, without limitation, a therapeutic action, in vivo tracking. In one particular embodiment of this invention the said conjugation is done with Rhodamine B as an active ingredient in nano-tubes prepared with lauric side chain, which show red fluorescence derived from Rhodamine B and is useful for in vivo tracking. The ingestible nano-tubes made from PABA moiety show excellent shelf life, biocompatibility, potential low immunogenicity and potential freeness from other physiological hurdles in vivo application of nanomaterials. Utility has also been pointed out to optimize pill-like properties for orally ingested materials as micropills to deliver biomaterials for effective gene therapy and novel cargoes for molecular populations.